The administration of therapeutic antibodies via injection is becoming an increasingly popular treatment method for a growing number diseases and indications having broad implications for patient health and well-being.
The inherent instability of protein drugs has led to a number of challenges as the developers of injectable antibodies attempt to deal with packaging, handling, reconstitution and drug administration issues. These challenges are being compounded by the trend to patient self-medication, as population demographics and efforts by managed care providers to control healthcare costs drive the growth in drug self-administration, particularly for chronic conditions. This trend is introducing a new class of naive users to parenteral drug delivery.
A recent report by Research and Markets, "Injectable Antibodies. Products, Markets, Players and Forecasts", analyzes twenty-six injectable/Infusible therapeutic antibody drugs and examines key packaging, dosing, regulatory, economic and competitive factors that represent opportunities, risk factors and potential barriers to commercial success.
- Provides detailed analysis of injectable antibody market segments, market dynamics and market demographics
- Analyzes products, therapeutic demand drivers and evaluates commercial drug products in more than two dozen injectable antibodies
- Analyzes technologies and market development issues for injectable antibodies
- Provides market data and forecasts to 2016
- Profiles market participants, their product development activities, business strategies, and corporate alliances and affiliations